The U.S. medical establishment is disregarding a significant science report sponsored by the British government that criticizes transgender medical practices, as reported by the New York Times.
The Cass Report, commissioned by Britain’s National Health Service (NHS), discovered little scientific evidence to support the use of puberty-blocking drugs and surgeries as effective treatments for gender dysphoria in minors. Despite this, the U.S. medical community is standing firm in its support of the transgender movement and ignoring the findings of the report.
The report, led by Dr. Hillary Cass, former president of the Royal College of Pediatrics and Child Health, conducted a thorough review of scientific studies on transgenderism and consulted with various stakeholders. It found that the evidence supporting puberty-blocking drugs and hormonal treatments for kids is weak. As a result, the NHS has halted approval for these therapies and is moving away from hormone treatments.
Several European countries, including the UK, Denmark, Finland, Sweden, and France, have also started to distance themselves from the “affirmation” model of transgender treatment. However, the U.S. medical establishment, including the American Academy of Pediatrics and the Endocrine Society, continues to support gender-affirming care for transgender individuals, dismissing the findings of the Cass Report.
Despite the lack of evidence supporting transgender medical procedures for children, the Cass report does not reject these procedures entirely. It simply highlights the need for more research and evidence to determine their long-term effectiveness.
Overall, Dr. Cass emphasizes the importance of basing healthcare decisions on evidence and ethics, rather than political considerations. She challenges the U.S. medical community to consider multiple perspectives on transgender healthcare and prioritize the well-being of patients over political agendas.
